
|Videos|December 8, 2017
Dr. Graff Discusses Sipuleucel-T in Patients With mCRPC
Author(s)Julie Graff, MD
Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses sipuleucel-T (Provenge) in patients with metastatic castration-resistant prostate cancer.
Advertisement
Julie Graff, MD, assistant professor of medicine, OHSU Knight Cancer Institute, discusses sipuleucel-T (Provenge) in patients with metastatic castration-resistant prostate cancer (mCRPC).
Sipuleucel-T is well tolerated in this population, says Graff. Some patients have some itching or a slight fever, but both are both easily managed.
Although it has shown benefit, one of the challenges with sipuleucel-T is that it does not shrink tumors, Graff adds.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5




































